full issue - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 5 (3) 1309-1317 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online)
1315
References
1. Human Papillomavirus and Related
Cancers in India. (2010). WHO/ICO
Information Centre on HPV and Cervical
Cancer (HPV Information Centre)
Summary Report: 4-5
Fig. 6. Western blot analysis demonstrating specific
reactivity of Pichia pastoris expressed HPV 16 L2
protein with anti-HPV 16L2 peptide (40-150 amino
acids) monoclonal antibody showing protein band at
approximately 55 KDa. Lane marked “GS” was
loaded with non-recombinant Pichia pastoris strain
GS115 cell lysate.
investigations are required to ascertain these
observations in Pichia pastoris.
Conclusion
The available HPV L1 Virus like particle
based vaccines provide type specific protection
against the HPV genotypes associated with the
cervical cancer. Although there are reports of the
VLP based vaccines to provide cross protection
to the HPV types that are phylogenetically similar
to the vaccine types, these are limited both in
spectrum and levels of protection. Development
of a vaccine offering cross protection to a wide
variety of HPV types that cause cervical cancer
remains a challenging task. Some investigators
have reported that cross-reactive antigen derived
from the minor capsid protein L2 may offer a
possible alternative to multivalent L1 VLP
vaccines for protection against infection with
high-risk HPV types (25). A multimeric L2
peptides derived from different HPV types is
under clinical evaluation (26). This work is a
preliminary step towards exploring the utility of
full length HPV L2 as prophylactic vaccine for
cervical cancer.
2. Parkin, D.M., Louie, K.S. and Clifford, G.
(2008). Burden and trends of type-specific
human papillomavirus infections and
related diseases in the Asia Pacific region.
Vaccine. S26: M1-16.
3. Doorbar, J. (2005). The papillomavirus life
cycle. J. Clin. Virol., 32 (Suppl 1):S7–S15.
4. IARC monographs on the evaluation of
carcinogenic risks to humans. Human
papillomaviruses. (2007). IARC: Lyon:
IARC Press. 90: 179-327.
5. Burd, E.M.(2003). Human papillomavirus
and cervical cancer. Clin.Microbiol. Rev.,
16: 1-17
6. De Villier, E.M., Fauquet, C., Broker, T.R.,
Bernard, H.U. and zur Hausen, H.(2004).
Classification of papillomaviruses.
Virology. 324: 17–27
7. Harper, D.M., Franco, E.L., Wheeler, C.,
Ferris, D.G., Jenkins, D., Schuind, A.,
Zahaf, T., Innis, B., Naud, P., De Carvalho,
N.S., Roteli-Martins, C.M., Teixeira, J.,
Blatter, M.M., Korn, A.P., Quint, W. and
Dubin, G. (2004). Efficacy of a bivalent L1
virus-like particle vaccine in prevention of
infection with human papillomavirus types
16 and 18 in young women: a randomised
controlled trial. Lancet. 364 (9447):1757-
65.
8. Hagensee, M.E., Yaegashi, N. and
Galloway, D.A. (1993). Self-assembly of
human papillomavirus type 1 capsids by
expression of the L1 protein alone or by
Expression of recombinant minor capsid protein of HPV in Pichia pastoris